Abstract
The present work is focused on the identification of 2‐chloro‐5‐(1‐hydroxy‐3‐oxoisoindolin‐1‐yl) benzenesulfonamides (5a–5k) Schiff bases as potent urease inhibitors. The rationale behind the urease activity was to introduce lead candidate for the treatment of GIT disorders including gastric and peptic ulcer and hepatic encephalopathy. The synthesized compounds exhibited excellent anti‐urease activity which was further supported by in‐silico investigations. Therefore, it can be suggested that these derivatives can be considered as a potential lead in future for synthesis of potent inhibitors.
Schiff bases as the potential inhibitors of urease enzyme.